Department of Renal Medicine, Division of Medicine, University College, London, UK.
Institute of Biomedical Engineering, University of Oxford, UK.
J Control Release. 2019 May 10;301:166-175. doi: 10.1016/j.jconrel.2019.03.017. Epub 2019 Mar 20.
The development of new modalities for high-efficiency intracellular drug delivery is a priority for a number of disease areas. One such area is urinary tract infection (UTI), which is one of the most common infectious diseases globally and which imposes an immense economic and healthcare burden. Common uropathogenic bacteria have been shown to invade the urothelial wall during acute UTI, forming latent intracellular reservoirs that can evade antimicrobials and the immune response. This behaviour likely facilitates the high recurrence rates after oral antibiotic treatments, which are not able to penetrate the bladder wall and accumulate to an effective concentration. Meanwhile, oral antibiotics may also exacerbate antimicrobial resistance and cause systemic side effects. Using a human urothelial organoid model, we tested the ability of novel ultrasound-activated lipid microbubbles to deliver drugs into the cytoplasm of apical cells. The gas-filled lipid microbubbles were decorated with liposomes containing the non-cell-permeant antibiotic gentamicin and a fluorescent marker. The microbubble suspension was added to buffer at the apical surface of the bladder model before being exposed to ultrasound (1.1 MHz, 2.5 Mpa, 5500 cycles at 20 ms pulse duration) for 20 s. Our results show that ultrasound-activated intracellular delivery using microbubbles was over 16 times greater than the control group and twice that achieved by liposomes that were not associated with microbubbles. Moreover, no cell damage was detected. Together, our data show that ultrasound-activated microbubbles can safely deliver high concentrations of drugs into urothelial cells, and have the potential to be a more efficacious alternative to traditional oral antibiotic regimes for UTI. This modality of intracellular drug delivery may prove useful in other clinical indications, such as cancer and gene therapy, where such penetration would aid in treatment.
开发高效的细胞内药物输送新方法是许多疾病领域的重点。其中一个领域是尿路感染(UTI),这是全球最常见的传染病之一,给经济和医疗保健带来了巨大负担。已经证明,常见的尿路致病性细菌在急性 UTI 期间会侵入尿路上皮壁,形成潜伏的细胞内储库,从而逃避抗生素和免疫反应。这种行为可能促进了口服抗生素治疗后的高复发率,因为口服抗生素无法穿透膀胱壁并积累到有效浓度。同时,口服抗生素也可能加剧抗生素耐药性并引起全身副作用。我们使用人尿路上皮类器官模型,测试了新型超声激活脂质微泡将药物递送到顶细胞细胞质中的能力。充有气体的脂质微泡用含有非细胞渗透性抗生素庆大霉素和荧光标记物的脂质体进行了修饰。将微泡悬浮液添加到膀胱模型的顶表面的缓冲液中,然后用超声(1.1MHz,2.5Mpa,20ms 脉冲持续时间 5500 个循环)处理 20s。我们的结果表明,使用微泡进行超声激活的细胞内递药是对照组的 16 倍以上,是与微泡无关的脂质体的两倍。此外,没有检测到细胞损伤。总之,我们的数据表明,超声激活的微泡可以安全地将高浓度的药物递送到尿路上皮细胞中,并且有可能成为 UTI 传统口服抗生素治疗方案的更有效替代方案。这种细胞内药物输送方式可能在其他临床适应症中证明是有用的,例如癌症和基因治疗,在这些适应症中,这种穿透有助于治疗。